PDF
Citation
Print
INTRODUCTION
Achieving target glycosylated hemoglobin (HbA1c) while minimizing hypoglycemia has always been a challenge for diabetes treated with insulin [1]. However, technological advances including continuous glucose monitoring (CGM), connected insulin pens (CIPs), insulin pumps, and automated insulin delivery (AID) algorithms combined with education have made it possible to achieve the optimal control of diabetes using insulin (Fig. 1) [2,3]. In addition, cloud-based data collection programs can support diabetes and healthcare providers (HCPs) to make the optimal decision easily by offering various data from various devices such as glucose trend data, carbohydrate intake, insulin on board (IOB), and a bolus calculator in one platform [4]. These are of great importance in improving the glycemic status. These programs can even help to support decision-making by artificial intelligence (AI) algorithms [5].
We review the detailed information on present and future expectations for CGM, CIPs, AID systems, and virtual platforms. In addition, we report how they affect glycemic outcomes while minimizing the burden of diabetes management and demonstrate that the greatest benefit occurs when coupled with structured education. We especially focused on CGMs and the new emergence of CIPs. Only the CGM and devices integrated with CGM are outlined here.
CURRENT AND FUTURE CGM TECHNOLOGIES
Present CGM systems
The first CGM system was approved by the U.S. Food and Drug Administration (FDA) in 1999. The glucose data in this system was blinded to patients or HCP [6]. As the glucose levels were not available in real-time, the data were analyzed retrospectively after the use of CGM. Further, the data was only collected for 3 days with poor accuracy. Because of this limited accuracy, the early CGM was approved as an adjuvant to self-monitoring of blood glucose (SMBG) to reduce the number of fingerstick measurements.
However, the Dexcom G5 (Dexcom, San Diego, CA, USA) reached an accuracy of 9.0% mean absolute relative difference (MARD) similar to the glucose meter devices of MARD below 10%. Thus, in 2016, the FDA approved this as a non-adjunctive device that could replace fingerstick glucose monitoring when making treatment decisions [7,8]. This approval has led to other CGMs with similar accuracy. Nowadays, some CGM devices (e.g., Dexcom G6, G7, FreeStyle Libre 1,2,3 [Abbott Diabetes Care, Alameda, CA, USA], and Guardian Sensor 4) are precalibrated in the factory, and therefore do not require calibrations to adjust sensor accuracy. In 2021, the definition of professional CGM has changed to devices that are owned and applied in the clinic, regardless of whether the data provided are blinded or unblended [9].
With the steady improvement in sensor accuracy, duration of wear, and smaller size, the use of CGM is expanding widely. There are several CGM devices in current use, which are summarized in Table 1. The Dexcom G6 specified for 10-day wear is the first interoperable device with an AID system. It offers accurate readings during euglycemia and even in hypoglycemia without calibration (overall MARD: 10%, in hypoglycemia with glucose level <54 mg/dL and mean absolute differences: 10.8 mg/dL) [10]. However, the size (45×30×15 mm) of the device is a bit larger than FreeStyle Libre, and the transmitter and sensor are not combined but separated.
Abbott FreeStyle Libre is an intermittent scanning CGM (isCGM). It is also known as flash glucose monitoring (FGM) which requires scanning for the storage of the glucose value measured and does not provide hypo/hyperglycemia alarms. However, with third-party transmitter devices (e.g., Miao Miao and Bubble Mini), the measured glucose value can be transferred to a smartphone and could be used like a real-time CGM (rtCGM). It is comfortable with a small size sensor (35×5 mm), could be worn up to 14-day long, and does not need calibration. The MARD was estimated to be 11.4%, slightly higher than 10.0% [11]. Fortunately, an updated algorithm applied to FreeStyle Libre 2 has been used since 2021 in it, and the MARD achieved 9.2% in adults and 9.7% in pediatrics when the sensor is applied to the upper arm [12].
FreeStyle Libre 2 became available in 2020, it has optional alarms for hypo/hyperglycemia compared to FreeStyle Libre. With the advantage of optional alarms, users can choose to turn the alarm on or off. Another advantage is that the alarm is not consistent when once it is confirmed. Thus, it is suitable for subjects who suffer from alarm fatigue. The sensor accuracy of the MARD was improved as we mentioned above [12]. In addition, as with Dexcom G6, the device was approved as an integrated (or interoperable) CGM in August 2021. However, it is still FGM.
The Medtronic Guardian 3 sensor (Medtronic, Northridge, CA, USA) was approved by the FDA in February 2018. However, the device still needs calibration twice a day, and can only be worn for up to 7 days [13]. The device integrates with pumps in Medtronics (Minimed 640G, and 670G) but not with others. In May 2021, Medtronics developed the Guardian 4 sensor with the same 7-day duration of wear but requiring no calibrations. The device integrates with newly developed technology, the advanced hybrid closed-loop system (HCLS) MiniMed 780G, and a CIP called InPen [14,15].
patients who have skin reactions to adhesive [9]. With Eversense, skin eruption can be reduced by changing the siliconebased adhesive every day.
Future CGM systems
There are potential options for the use of CGM in the management of diabetes in the near future. Dexcom G7 received a CE mark in Europe in March 2022. Compared to the Dexcom G6, Dexcom G7 has several advantages. Dexcom G7 not only has improved in accuracy but has also improved in terms of features and size. It provides more accurate glucose readings than Dexcom G6, in that the overall MARDs for the arm and abdomen were 8.2% and 9.1%, respectively [17]. The G7 combined sensor and transmitter in a single body (all-in-one wearable) and is 60% smaller than the Dexcom G6. Skin reaction to an adhesive patch might be reduced by the smaller size of the patch area. The warm-up period was shortened to 27 minutes compared to 2 hours in G6. G7 also has advantages for those who suffer from alarm fatigue because the audible glucose alerts can be disabled for up to 6 hours. The CGM wear time was extended to 10.5 days from 10 days before. Dexcom announced that the FDA submission of the G7 CGM system may expand from a 10- to a 15-day sensor, and this might benefit the cost per device [18].
Following the technological trend of rtCGM, Abbott launched FreeStyle Libre 3, which transitioned from isCGM to rtCGM, in March 2022. It was cleared for a CE mark in September 2020, and FDA approval in May 2022. The device is now only available in the UK at the timing of writing. Compared to FreeStyle Libre2, the size has been reduced by more than 70%. It has the same accuracy and the same length of wear time (14 days) as FreeStyle Libre 2 [12].
Eversense E3 could be implanted for 180 days and received a CE mark in June 2020. In February 2022, the FDA also approved it and now it is available in the USA. Although the sensor time is increased up to 180 days (6 months), a disadvantage is that calibration is still required [19]. Fortunately, the number of calibrations reduces from 2 times/day for 21 days, to 1 time/day after day 21.
We anticipate that future diabetes technology with non-invasive CGM could be worn on the wrist. Recently, HGR GWave, non-invasive radiofrequency sensing, showed accurate results in five subjects with type 2 diabetes mellitus (T2DM). The HGR readings had a high correlation with glucose measurements at R2=0.924 (P<0.0001) [20]. Further clinical studies are needed to facilitate the use of non-invasive radiofrequency sensing for diabetes in actual practice.
GLYCEMIC EFFICACY OF CGM ITSELF
CGM has emerged as a useful tool to assess glycemic status and is consistently proved to be effective compared to SMBG alone in patients with type 1 diabetes mellitus (T1DM) and T2DM who are receiving insulin-based therapy [21-24]. Thus, we have reviewed the efficacy of different CGM systems (rtCGM vs. isCGM) with populations of different glycemic statuses to assist clinicians more comprehensively and provide guidance in the selection of an appropriate CGM. Two types of CGM are available: rtCGM and isCGM. In general, CGM refers to rtCGM that allows individuals to visualize real-time data in 1 to 5 minutes. IsCGM is referred to as FGM because the glucose value can only be seen by scanning the sensor; thus, it is regarded as a separate entity from CGM. As the glucose monitoring methods are different, they also have different glycemic effects.
The effectiveness of rtCGM has been confirmed in various randomized controlled trials (RCTs) with different types of diabetes and insulin regimens (Table 2). The glycemic outcome was different based on the glycemic status of the study population included. Studies showed that rtCGM had a beneficial effect on reducing HbA1c, particularly in patients with markedly high HbA1c, and on reducing hypoglycemia, especially in patients with a history of severe hypoglycemia. In studies with T1DM and T2DM both were poorly controlled using multiple daily injections (MDI; DIAMOND and GOLD), regardless of the type of diabetes, the rtCGM had the advantage of reducing HbA1c by 0.3% to 0.6% more than non-CGM users [21-23]. Specifically, in a study evaluating the HbA1c reduction in T1DM using MDI with a mean HbA1c of 8.6%, the mean differences of time in range (TIR, 70 to 180 mg/dL) were 5.4% (77 minutes/day) between the rtCGM and SMBG groups (P=0.005) [21]. Also, the time below range (TBR, <70 mg/dL) decreased from 4.5% to 3.0% at week 24 in the rtCGM users. Unfortunately, the T2DM trials did not show differences in hypoglycemia between the groups [23].
A notable finding is that there were no between-group differences in HbA1c or TIR in the study evaluating the incidence of hypoglycemia, in contrast to trials evaluating HbA1c reductions in individuals with high HbA1c. These results are from the included participants, who were patients with a high risk for hypoglycemia and with relatively lower portion of high HbA1c (with HbA1c lower than 9.0%). Thus, it is natural that hypoglycemic events were significantly reduced with the relatively high portion of hypoglycemia, and it is also natural that there’re were no differences in hyperglycemia between the groups because of the relatively lower portion of individuals with high HbA1c [25].
Trials were conducted on the effectiveness of rtCGM for treating T2DM with basal insulin and not MDI [24]. The study population included HbA1c between 7.8% to 11.5%, with a mean HbA1c of 9.0% for both the rtCGM and SMBG groups. The mean HbA1c level decreased to 8.0% in the rtCGM group with a mean adjusted difference of –0.4% (P=0.02) between the CGM and the SMBG group. The results were similar to those of the study of populations using MDI. Interestingly, they also explored the effect of discontinuing rtCGM after 8 months in the same population of T2DM using basal insulin [26]. In the study, TIR increased from 38% to 62% after 8 months of CGM use but decreased after discontinuing CGM to 50% at 14 months (mean change from 8 to 14 months –12%, P=0.01), emphasizing the importance of consistent CGM use.
The glycemic outcomes from isCGM and rtCGM are different. The RCT outcomes of isCGM are listed in Table 3. There are not many studies for isCGM, isCGM did not show an HbA1c reduction even in a study with poorly controlled diabetes (HbA1c range, 7.5% to 12.0%) [27]. Although the isCGM does not have the ability to reduce HbA1c, it still can be used to avoid hypoglycemia [28,29].
Several meta-analysis studies have compared the effects of rtCGM and isCGM on glycemic outcomes [30,31]. In a meta-analysis identifying 15 RCTs involving 2,461 patients, rtCGM led to higher improvements in mean HbA1c (0.23%) and TIR (5.8%), whereas isCGM was associated with a greater decline in TBR [31]. However, this meta-analysis was performed without considering the purpose and baseline characteristics of the study. In studies aimed at improving HbA1c or TIR, poorly controlled diabetes with high HbA1c were enrolled, but in the case of hypoglycemia prevention, subjects with a high risk of hypoglycemia were enrolled rather than subjects with a high level of HbA1c. It is relatively difficult to show a decrease in HbA1c in studies seeking to prevent hypoglycemia in a well-controlled population. Therefore, considering that the study differs HbA1c at entry, and differs primary outcomes, meta-analyses should be divided into the studies with HbA1c near target with the primary outcome of reduction in hypoglycemia, and high HbA1c with primary outcome of HbA1c reduction, separately [32].
EFFECT OF EDUCATION ON CGM USE
The use of rtCGM reduces HbA1c by about 0.3% to 0.6% [33]. Beck et al. [21] revealed that the HbA1c was 0.6% lower, and TIR was 5.3% (1.28 hour/day) higher in the rtCGM group than in the control group with poorly controlled T1DM. However, despite the benefits of rtCGM itself, subjects in the rtCGM group did not achieve the target of HbA1c <7.0% and TIR >70%. HbA1c and TIR only achieved 7.7% and 51.1% (12.3 hours/day), respectively. The use of rtCGM without education limits better glycemic outcomes.
Today, structured education specifically for CGM has been recognized as an essential part of diabetes therapy. By increasing the ability of the patient to adjust the insulin dose rather than using fixed-dose insulin, an additional glycemic improvement can be achieved. Several studies have noted the importance and effectiveness of education [34-38]. Yoo et al. [38] emphasized personalized education in a study comparing the efficacy of rtCGM combined with structured education or without education. In an RCT, participants with 3 months of structured education had a 15.3% (3 hours 42 min/day) increase in TIR compared with the control group. These results showed remarkable increases in TIR than in a previous study that used rtCGM without education. The group with education had a more HbA1c decrease of 0.5% compared to those without education. The HbA1c changed from 8.4% to 7.2%, nearly achieving an HbA1c of 7.0%. Studies with very young children and with children had similar results [34,36].
RCT studies showed that isCGM has high efficacy in reducing hypoglycemia whereas it does not improve HbA1c. However, users educated in isCGM improve glycemic outcomes. Hermanns et al. [35] showed a significant difference of –0.17% reduction in the HbA1c of an isCGM with education group compared to the isCGM without education. In addition, Yaron et al. [37] reported a 0.82% reduction of HbA1c for 10 weeks in isCGM users who had attended education for insulin dose adjustment.
EFFECTS OF CGM INTEGRATION WITH OTHER DEVICES
Currently available and future CIPs with CGM
A missed insulin injection, inappropriate timing of injection, and problematic adherence in patients with insulin-based therapy are common and have always been challenging [39]. These problems are related to an increase in HbA1c and eventually lead to increases in diabetes complications [40].
The CIP is a new technology with a function that displays the last dose of insulin and timing and has reminder alerts that integrate with a smart app. Today, with greater advances in the technology of the CIP, it integrates with CGM and even integrates with mobile apps to help users to calculate bolus doses easily with a bolus calculator, and finally, all the data are submitted to a virtual platform. Several studies have shown that the emergence of new technologies overcome barriers and report better glycemic outcomes than pens without the function [41-43]. Currently, a few clinical trials are collecting data on the effectiveness of these CIPs.
An overview of the characteristics of CIPs and smart cap integrating with CGM is summarized in Table 4. In 2017, the Medtronic InPen (Companion Medical, San Diego, CA, USA) became the first FDA-approved CIP [44]. The InPen, a Bluetooth-enabled wireless insulin pen, has functions that not only memorize the number of doses and timing of insulin injections in rapid acting insulin but it also has a bolus calculator and IOB display like insulin pumps. The display of injection timing with IOB helps to prevent insulin stacking. With the bolus calculator, the users can calculate the appropriate doses easier, like pump users. Thus, a device with the bolus calculator function, not limited to InPen, can be a good choice for patients with diabetes who want to optimize bolus doses with correction factors (CF), insulin-carbohydrate ratio (ICR), and duration of insulin actions, but are hesitant about always attaching the devices. The bolus calculator in the mobile app of InPen also has a simple version like ‘meal size estimation (small, medium, or large)’ for individuals with diabetes who are unfamiliar with carbohydrate counting. It also has alerts for injection reminders to help avoid injection omission.
The benefit of the CIP is not only in diabetes, but it also helps HCPs to make better decisions in diabetes management by engaging diabetes with correct insulin use information [45]. With the CIP, there is no need to make decisions about insulin doses, timing, or the number of insulin injections based on a presumption that the patient is following the insulin prescription. Data from the device integrate with CGM in one platform. Thus, with a CIP, the glucose values and the amount of carbohydrate intake, and the amount and time of the insulin dose can be seen at a glance. The importance of the device is the benefits in glycemic outcomes, but the number of studies is limited. Vigersky et al. [46] reported an increase in TIR of 2.3% (0.6 hour/day) and a decrease in time above range (TAR >180 mg/dL) of 2.4%, with no change in TBR in the InPen users compared to pre-InPen use in poorly controlled T1DM (glucose management indicator >8.0%) when combined with CGM.
NovoPen 6 and NovoPen Echo Plus by Novo Nordisk (Bagsværd, Denmark) are CIPs similar to InPen; they automatically memorize insulin doses and timing and further integrate with CGM. The devices have not yet been cleared by the FDA [42]. Compared to InPen, which works with Bluetooth, the Novopen 6/Echo Plus works with near-field communication technology. In addition, the battery life of the Novopen6/Echo Plus (5 years) is much longer than those of InPen (1 year) without recharging. In collaboration with Glooko/Diasend (Gothenburg, Sweden) digital diabetes management platforms, the information obtained by NovePen6/Echo Plus can be integrated with various CGMs available in Glooko. However, it does not offer injection reminders or IOB display. Two observation studies have evaluated the efficacy of NovoPen 6 integrating with CGM, one in adults and the other in pediatric patients [42,43]. Adolfsson et al. [42] revealed significant changes during the 12-month follow-up period, with an 8.5% (1.9 hour/day) increase of TIR, 6.2% decrease of TAR (>180 mg/dL, 1.8 hour/day), and 1.5% TBR (<54 mg/dL, 0.3 hour/day) in 94 patients with T1DM. They also found that missed bolus dose (MBD) injections decreased by 43% over the study (P=0.0002). In another study, they found that the TBR (<54 mg/dL) reduces by 0.64% from 2.82% to 2.18% in at least 12 months of follow-up in 39 pediatric patients with T1DM. However, there were no changes in MBD meals, TIR, and TAR (>180 mg/dL) [43].
Bigfoot Biomedical received FDA approval as a diabetes management system featuring connected insulin caps for an insulin pen in 2021 [47]. It is the only smart cap solution that works with disposable insulin pens integrated with FreeStyle Libre 2, and it will also be available with FreesStyle Libre 3 soon. It has similar features to the InPen. It offers a bolus calculator, IOB display, missed dose reminder, and hypoglycemia alarm and combines this with the Bigfoot Unity mobile app. Caps are available for both basal and rapid-acting insulins compared to the InPen, which only has rapid-acting insulins. There are two smart pen caps, a white one for rapid-acting (bolus) insulin and a black one for long-acting (basal) insulin. Data for both rapid-acting insulins and long-acting insulins are presented in one place in the Bigfoot Unity mobile app. Lilly launched the Tempo pen and a small smart button device that attaches to a prefilled tempo pen [41]. A study has shown the benefits of the smart button integrated with rtCGM (Dexcom G5) in TIR, TAR, and TBR, and also in MBD [41]. It was a 12-week, single-arm, exploratory, two-period study for subjects with T1DM (n=38) or T2DM (n=26). MBD significantly decreased from 0.74 to 0.62 MBD/day (P=0.008). In addition, TAR, TBR, and mean HbA1c decreased from 53.6% to 48.1% (P=0.004), from 4.49% to 2.93% (P<0.001), and from 8.8% to 8.4% (P<0.001), respectively. TIR also increased significantly from 41.9% to 49.0% (P<0.001).
We have reviewed the CIPs and caps that are currently on the market, and several are expected to be on the market soon. Diaconn (Seoul, Korea) P8 of the CIP by G2E, and SoloSmart Mini [48] of smart caps by Sanofi (Paris, France) are also in development. SoloSmart Mini is a reusable insulin pen cap that enables the recording of insulin doses and the timing of injections. The SoloSmart Mini will be launched in Korea at the end of 2022. Diaconn P8 allows 0.1-unit increments of dosing and a bolus maximum of 300 units with various insulin cartridges and CGMs. The device has an in-built bolus calculator, IOB, and last doses of insulin injections on display. As with the CIP by Bigfoot Biomedical, they have separate pens for basal and rapid-acting insulins. Both CIP and insulin pump of G2E can be linked with and can be shown in just one App, thus users can switch the two devices flexibly whenever the user wants.
Currently available and future insulin pumps with CGM
Increasing evidence demonstrates the effectiveness of insulin pumps when used in combination with a CGM and closedloop algorithm controller to automate basal insulin delivery, these are known as HCLS [50-52]. The outcomes are well summarized in the review article by Moon et al. [53]. Thus, this review only includes updated clinical trials beyond the previous review article (Table 5).
AID systems are becoming more advanced. Of these devices, the clinical benefits of advanced HCLS (AHCLS) are among the highlights. AHCLS differs from HCLS, which modulates basal insulin delivery but does not administer automated correction boluses. AHCLS has an additional function with automated bolus correction. Medtronic MiniMed 780G is the first AHCLS which includes a target set point of 100 or 120 mg/dL and an automated correction bolus feature up to every 5 minutes. The RCT showed 12.5% higher TIR in AHCLS compared to the sensor augmented pump (SAP) therapy with predictive low-glucose suspend (PLGS, 70.4% vs. 57.9%, P<0.001) in 59 patients with T1DM previously using insulin pump therapy [54]. Recently in a single-arm prospective study involving 157 adolescents and adults with T1DM, the study revealed an additional increase in TIR of 5.7% (increased from 68.8% to 74.5%, P<0.001) as a result of conversion from SAP with PLGS to AHCLS for 3 months [55]. Compared with the run-in period, AHCLS reduced HbA1c from 7.5% to 7.0%, a decrease of 0.5%, and TBR (<70 mg/dL) decreased from 3.3% to 2.3% (all P<0.001). In addition, when the target was set to 100 mg/dL, TIR increased to 75.4%. The results were similar in other prospective single-arm study with 34 children and adolescents for 12 weeks of treatment [56]. Glycemic efficacy in the study was different because the study population was consisted of T1DM with MDI therapy, not insulin pumps before the study entry. Furthermore, 10 days of education was added. Remarkably, TIR increased from 42.1% at baseline to 78.8% in the study phase (P<0.001). HbA1c decreased from 8.6% at baseline to 6.5% at the end of the study (P=0.001). Thus, with the advance in technology and structured education, the glycemic outcomes could be remarkably improved even when the patients have less burden with automated bolus correction. We await the results of the Advanced Hybrid Closed-Loop in an Adult Population with Type 1 Diabetes (ADAPT) study comparing AHCLS to CGM with MDI [57].
Although not as sophisticated as the MiniMed 780G, the Tandem T:slim X2 also performs bolus correction every hour, so it is sometimes classified as AHCLP. Existing RCTs also consistently showed an 11% TIR increase compared to SAP [51]. For the entire 12-month observation of a real-world study of 9,451 users of the t:slim X2 insulin pump with Control-IQ technology, TIR increased from 63.6% to 73.6%, exceeding the target value of TIR 70% with no increase in hypoglycemia (TBR <70 mg/dL: <1%) [58].
The Insulet Omnipod 5 (Insulet, Acton, MA, USA) is in the spotlight as the first tubeless patch pump with an algorithm in the pod that has FDA approval, although it is still HCLS, which does not have bolus auto-correction. The tubeless patch pump, as the name suggests, has several advantages, for example, it does not have a long tube line and it is in the form of a small patch, giving the convenience of wearing comfort. A multicenter prospective study involving 235 patients with T1DM resulted in a 0.71% HbA1c reduction in children and a 0.38% reduction in adults [59]. In addition, TIR was improved from standard therapy by 15.6% (3.7 hours/day) in children and 9.3% (2.2 hours/day) in adults (both P<0.0001). A study for very young children also showed similar results [60].
The insulin-only iLet Bionic Pancreas (Beta Bionics, Irvine, CA, USA) with greater automation can significantly reduce the burden of T1DM and also showed good results in the ADA conference of 2022 [61]. It differs from currently marketed artificial pancreas systems (APSs) in that users do not need exact carbohydrate counting, just simple input such as “typical, larger, or smaller meals than usual.” In addition, users only need to enter their body weight to initialize the system with no run-in period before automation. In that the ultimate goal of the AID system is to reduce the burden of T1DM through full automation, this device is closer to the future. The study comparing iLet Bionic Pancreas (integrated with Dexcom G6) to a standard of care involving currently available APS or SAP integrated with CGM or MDI with CGMs, showed the benefits for 440 adults and children with higher HbA1c levels during 13 weeks of treatment. In the iLet group, the HbA1c changed from 7.6% to 7.1%, and the mean difference between the iLet and control group was 0.5% (P<0.001). The TIR was 11% (2.6 hours/day) higher than the control group (P<0.001). There was no difference in TBR <54 mg/dL in both groups, but all groups achieved the target below 1%. However, even in patients with poorly controlled diabetes, at the study end, TIR was only 69% in adults, so caution is needed in selecting this iLet Bionic Pancreas for those with well-controlled diabetes.
Do-it-yourself closed-loop systems with CGM
Do-it-yourself closed-loop (DIY) systems are open-source algorithms designed to automate insulin delivery that link to existing CGMs and insulin pumps. These systems were created before the first commercial AID systems received FDA approval in 2016 by an online community (non-profit organization) who were directly related to diabetes. Thus, are freely available on the internet by app and are easily accessible. However, since they have not received FDA approval, they cannot be prescribed by the HCP and the patient has to take full responsibility for the failure of DIY. There are three types of DIY available: Open APS, Android APS, and Loop. Android APS does not require additional hardware except with Medtronic pumps or Omnipod; however, Open APS and Loop require additional hardware called “Rig” and “Riley Link,” respectively.
The evidence of safety and effectiveness from real-world studies is growing [62]. In these studies, the glycemic efficacy is similar to commercially available systems [63-65]. A prospective real-world study for the safety and effectiveness of the Tidepool Loop (Tidepool, Palo Alto, CA, USA) open-source AID system was published [64]. The TIR increased from 67% to 73% over 6 months and decreased severe hypoglycemia (TBR <54 mg/dL) by 0.05% (All P<0.01). Mean HbA1c decreased with a mean difference of 0.33%, even in subjects with a mean HbA1c of 6.8%. With this growing evidence, Tidepool has submitted the Loop algorithms to the FDA to build a commercial version. We hope that these DIYs will be FDA-approved and used more safely. Recently, the first RCT comparing Android APS to SAP was shown at the ADA 2022 conference. The mean TIR was 74.5% using Android APS achieving the TIR of 70%, but only 56.4% was shown in the SAP group [66].
GLYCEMIC MONITORING PLATFORMS
Factors that have greatly improved glycemic status include CGM, an AID system, CIPs, and structured education programs but the area of particular importance is a glycemic monitoring platform [67]. It collects the data from all of the above and allows the HCP and patients to see various and accurate information at a glance. This helps both the patients and HCPs to make better decisions for glycemic improvement by recommending the optimal basal rate, CF, and ICR [68]. These cloud-based data collection programs include Tidepool, Glooko/Diasend, Jade Diabetes (Victoria, Australia), and MySugar (Vienna, Austria) available worldwide, and Diaconn web only available in Korea.
These free online platforms allow the user to integrate with various types of CGM, glucose meters, insulin pumps, and CIPs. Large companies such as Glooko/Diasend and Tidepool have similar abilities to provide glucose trends, amount of carbohydrate intake, basal and bolus dosages, exercise, and other biometric factors. However, the device compatibility is different. Both Glooko/Diasend and Tidepool integrate with CGMs by Dexcom and Abbott and insulin pumps by Insulet, Tandem, and Medtronics, and CIPs from Medtronics InPen. The Glooko/Diasend does not support CGMs by Medtronics (e.g., Guardian connect, Guardian 3 sensor), on the other hand, Tidepool does not support CIPs from Novo Nordisk (Novopen 6/Echo plus). Diaconn web is organized by G2E and only available in South Korea. The platform has similar abilities to Glooko in reporting data. However, they only support their own insulin pump (Diaconn G8) and CIP (Diaconn P8), and other CGMs of Dexcom G6, and FreeStyle Libre with a thirdparty transmitter. Jade Diabetes recently launched the voice-based insulin dosing system, Alexa.
THE FUTURE OF DIABETES THERAPY INTEGRATED WITH CGM
The advancement of CGM has enabled a complete glucose profile to be obtained, thus making it possible to diagnose the glycemic status of an individual precisely. The device is getting smaller, more comfortable to wear, accurate, and even non-invasive glucose monitoring technologies are in development [69]. In addition, the advancement of the AID system and CIP integrated with CGM has reduced the burden of T1DM by overcoming the time consumed on insulin management. The development of diabetes technology made it possible to avoid hyperglycemia without increasing hypoglycemia with a more comfortable fit and less effort, which could not previously be shown in diabetes with insulin therapy [70].
In the future, we expect that a fully automatic AID system will emerge, just as Bionic Pancreas has developed no carbohydrate counting pumps, which was previously burdensome for users. However, most of the HCLS still need to modify a variety of parameters including carbohydrate counting, and these require expertise and experience from the HCP. Thus, as there is a platform where you can see various technologies in one place, it is necessary to develop a decision support tool that can help with complex insulin dose calculating over a short time through that platform for optimal management. Indeed, Glooko has made a digital decision support system called DreaMed Advisor Pro (DreaMed Diabetes Ltd., Petah Tikva, Israel) which automatically provides the exact insulin dosing recommendations and other treatment tips through an AI-based algorithm [71]. In a study comparing physicians to DreaMed Advisor Pro in insulin dose adjustment, the changes in insulin dosing were similar to those given by the physicians.
CONCLUSIONS
It has become possible to fully diagnose an individual glycemic status through rapidly evolving CGM technology. CGM use is growing exponentially with valuable benefits on clinical outcomes, furthermore, various technologies can be integrated with it. These complex bunch of data including glucose trend, amount of carbohydrate intake, IOB, and physical activity are summarized in a virtual platform, which helps the HCP and patients with diabetes easily analyze and helps diagnose the glycemic status. This has resulted in a dramatic improvement in glycemic control. There is no doubt that evolving diabetes technology has changed the treatment paradigm for patients with diabetes using insulin treatment and reduced the burden of diabetes self-management such as the adjustment of insulin dosing. However, the burden of the disease is significant. Despite the technological advances, accessing new technology with complexity and rapid changes could be a burden to some patients if it is not fully automated. Thus, in the future, we expect the CGM to be smaller, more comfortable, last longer, and, importantly, be more accurate. In addition, we expect the advancement of the AID system with a fully automatic algorithm according to the meaning of the term “artificial pancreas system,” which no longer needs carbohydrate counting or meal estimation. Currently, all the information from the CGM and integrated devices are connected to the virtual platform, but a tool for decision support is in development, so the vast information may feel rather complicated. Thus, constant efforts for developing AI-based personalized decision support such as DreaMed advisor, which recommends adjustments to the CF, ICR, and basal rate automatically, are needed to optimize insulin use in diabetes aiming to accomplish the greatest TIR with no hypoglycemia.
XML Download